The overall seroprevalence of below 10 per cent in India indicates that a large proportion of the population remains susceptible to novel coronavirus infection.
Mutation typically refers to the property of a virus to undergo changes when it multiplies and the virus may develop some new strains after it replicates.
Emergency use for COVID-19 vaccine to depend on trial data; roll-out of FELUDA test expected soon: Vardhan
Presently COVID-19 vaccines are in various stages of phases 1, 2 and 3 of human clinical trials, the results of which are awaited, Vardhan said during an interaction with his social media followers.
The 'antisera' has been developed by the Indian Council of Medical Research (ICMR) in collaboration with a Hyderabad-based bio-pharmaceutical firm.
Named after Satyajit Ray's famed detective, the Feluda test, which is priced at Rs 500 and can deliver a result in 45 minutes, is able to differentiate SARS-CoV-2 from other coronaviruses.
The generated high-powered microscopic images show a large number of the virus particles on human respiratory surfaces, ready to spread infection across tissues, and to other people.
The only thing that can be said with any degree of uncertainty is that antibodies is a sign that the person has already been infected with the novel coronavirus, the scientists said.
In the current study, published in the journal Science, the scientists designed a new version of this protein which can be produced up to 10 times more in cells.
The virus may then be exposed to the river water containing antiviral drugs, inducing antiviral selective pressures and mutations in the virus leading to antiviral drug resistance.
The SARS-CoV-2 virus that causes the dreadful infection is extremely resilient and can survive on surfaces much longer than expected.
The isolate sequences from Delhi which has 3.7% mortality were found to be distributed across both the major clusters and sub-clusters.s
The research body further tweeted that scientists from all over the country were invited to analyse these genomes.
Roche said that it had developed Elecsys Anti-SARS-CoV-2 immunoassay, which using a blood sample can detect antibodies to determine the body's immune reaction to the virus that causes COVID-19.